Tuberculosis and Respiratory Diseases

  • 제71권4호
  • /
  • Pages.286-290
  • /
  • 2011
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Erlotinib에 대한 내성 발생 후 Gefitinib에 반응한 진행성 폐선암 1예

Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma

  • 홍성철 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 심윤수 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 이진화 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 류연주 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 장중현 (이화여자대학교 의학전문대학원 내과학교실)
  • Hong, Sung-Chul (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Sim, Yun-Su (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Lee, Jin-Hwa (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Ryu, Yon-Ju (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Chang, Jung-Hyun (Department of Internal Medicine, Ewha Womans University School of Medicine)
  • 투고 : 2011.05.20
  • 심사 : 2011.06.28
  • 발행 : 2011.10.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Although failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of administering erlotinib as a second EGFR TKI after resistance of gefitinib as the first TKI has been well known. However, good response to gefitinib after an initial response to erlotinib has been rare. We report that a 45-year-old woman (never smoked), with lung adenocarcinoma and EGFR mutation, showed an initial response to erlotinib, and then responded to gefitinib again.

키워드

참고문헌

  1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. https://doi.org/10.1056/NEJMoa040938
  2. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, et al. Phase II study of erlotinib in advanced non-smallcell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-33. https://doi.org/10.1200/JCO.2006.10.4166
  3. Wong AS, Soong R, Seah SB, Lim SW, Chuah KL, Nga ME, et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008;3:400-4. https://doi.org/10.1097/JTO.0b013e318168c801
  4. Chang JW, Chou CL, Huang SF, Wang HM, Hsieh JJ, Hsu T, et al. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer 2007;58:414-7. https://doi.org/10.1016/j.lungcan.2007.05.018
  5. Gridelli C, Maione P, Galetta D, Colantuoni G, Del Gaizo F, Ferrara C, et al. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol 2007;2:758-61. https://doi.org/10.1097/JTO.0b013e3180cc25b0
  6. Kim HK, Ahn MI, Yoo J, Kim CH, Yang HJ, Shim BY. Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman. Cancer Res Treat 2007;39:37-9. https://doi.org/10.4143/crt.2007.39.1.37
  7. Wong AS, Seto KY, Chin TM, Soo RA. Lung cancer response to gefitinib, then erlotinib, then gefitinib again. J Thorac Oncol 2008;3:1077-8. https://doi.org/10.1097/JTO.0b013e318183afb0
  8. Wu SG, Shih JY, Yu CJ, Yang PC. Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. J Thorac Oncol 2008;3:451-2. https://doi.org/10.1097/JTO.0b013e318169e32a
  9. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92. https://doi.org/10.1056/NEJMoa044238
  10. Viswanathan A, Pillot G, Govindan R. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2005;50:417-8. https://doi.org/10.1016/j.lungcan.2005.07.004
  11. Fukui T, Otani S, Hataishi R, Jiang SX, Nishii Y, Igawa S, et al. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol 2010;65:803-6. https://doi.org/10.1007/s00280-009-1212-5
  12. Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7:51. https://doi.org/10.1186/1471-2407-7-51